Zhitong Finance App News, Alice (688578.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study of injectable AST1001 independently developed by the company to treat adult patients with locally advanced or metastatic solid tumors who have failed previous standard treatment was approved for drug clinical trials.

According to reports, AST1001 for injection is an antibody conjugation drug (ADC) independently developed by the company. It is composed of bispecific antibodies targeting the epidermal growth factor receptor (EGFR) and stromatal-epithelial cell conversion factor (c-Met) and the topoisomerase I (Topo‑I) inhibitor developed independently by the company. It is intended for the treatment of locally advanced or metastatic solid tumors that have failed in the past. In October 2026, the US Food and Drug Administration (FDA) approved a phase I clinical study of injectable AST1001 to treat adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.